Recreational Drugs Can Reduce Safety, Efficacy of Antiretroviral Agents

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

Recreational Drugs Can Reduce Safety, Efficacy of Antiretroviral Agents

Drug Week (12.20.02) - Friday, December 27, 2002
Michael Greer

Canadian researchers warn that illicit drugs can trigger potentially lethal side effects in HIV patients on antiretroviral therapy. Tony Antoniou and colleagues at Toronto General Hospital conducted a study to "summarize existing data regarding potential interactions between recreational drugs and drugs commonly used in the management of HIV-positive patients." The investigators reviewed data from studies in the MEDLINE database and a number of other sources including textbooks and conference abstracts. They found a number of recreational drugs - including MDMA (Ecstasy), heroin, and LSD - can dangerously alter the pharmacokinetics of protease inhibitors and other antiretroviral agents.

Antiretroviral drugs inhibit the cytochrome P450 metabolic pathway, which is used to break down antiretroviral agents and opioids, amphetamines and other classes of recreational drugs, the study reported. PIs and nonnucleoside reverse transcriptase inhibitors (NNRTIs) strongly suppress cytochrome P450-based drug metabolism and have been implicated in MDMA and gamma- hydroxybutyrate overdoses, data showed. Impaired metabolism of LSD, ketamine, methamphetamines, and phencyclidine (PCP) was reported for patients on PI therapy. Reactions seemed particularly severe for those prescribed ritonavir. The NNRTIs nevirapine and efavirenz hastened methadone metabolism and possibly triggered withdrawal symptoms, an effect also found in some PI-treated patients, said the study. The full report, "Interactions Between Recreational Drugs and Antiretroviral Agents," was published in Annals of Pharmacotherapy (2002; 36(10):1598-1613).

"Interactions between agents commonly prescribed for patients with HIV and recreational drugs can occur, and may be associated with serious clinical consequences," Antoniou and colleagues concluded. "Clinicians should encourage open dialog with their patients on this topic, to avoid compromising antiretroviral efficacy and increasing the risk of drug toxicity."
021227
AD022502

Copyright © 2002 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.